Go or no go? Abbvie, Roche and Kala await key decisions
One of the biggest drugs of the year, Abbvie’s Jak inhibitor upadacitinib, could get the nod in August.
Vanda preps Hetlioz for a new market
The company hails a partial clinical trial win as the way in to a new use for Hetlioz, but the stock markets are less convinced.
Upcoming events – Vanda Pharmaceuticals awaits two catalysts and Evofem tries again
A two-for-one holiday sale is coming for Hetlioz and tradipitant, and Evofem hopes to confirm its contraceptive gel's effectiveness.
